Amicus Therapeutics, Inc.
FOLD
Classificação em ações
#3694
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Preço da ação
$14.49
Última sincronização: 2026-04-27
Valor de mercado
$4.55B
Variação (1 dia)
0.00%
Variação (1 ano)
71.68%
País
US
Negociar Amicus Therapeutics, Inc. (FOLD)
Categoria
Healthcare
Lucros da Amicus Therapeutics, Inc. (FOLD)
Lucros em Dec 2025 TTM: $191.00K
De acordo com os últimos relatórios financeiros da Amicus Therapeutics, Inc., os ganhos atuais da empresa são de $191.00K. Em 2023, a empresa teve ganhos de $-150.10M, um aumento em relação a aos ganhos de 2022, que foram de $-242.04M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Amicus Therapeutics, Inc. de 2003 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $191.00K | -100.66% |
| 2024 | $-28.76M | -80.84% |
| 2023 | $-150.10M | -37.98% |
| 2022 | $-242.04M | 0.20% |
| 2021 | $-241.55M | -11.92% |
| 2020 | $-274.25M | -22.94% |
| 2019 | $-355.91M | 1.95% |
| 2018 | $-349.09M | -22.27% |
| 2017 | $-449.12M | 120.39% |
| 2016 | $-203.78M | 54.24% |
| 2015 | $-132.12M | 88.63% |
| 2014 | $-70.04M | 10.92% |
| 2013 | $-63.15M | 21.36% |
| 2012 | $-52.03M | 8.30% |
| 2011 | $-48.04M | -14.33% |
| 2010 | $-56.08M | 753.89% |
| 2009 | $-6.57M | -83.31% |
| 2008 | $-39.36M | -4.40% |
| 2007 | $-41.17M | -11.17% |
| 2006 | $-46.34M | 125.15% |
| 2005 | $-20.58M | 0.00% |
| 2004 | 0.00 | -100.00% |
| 2003 | $-6.77M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | 2,761,627.75% |
US
|
|
| $-3.09B | -1,616,330.37% |
US
|
|
| $-4.02B | -2,102,820.66% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,021,182.77% |
NL
|
